#TURALIO
LightNews LightNews
icglocal600.bsky.social
Congratulations to the Turalio commercial crew in Los Angeles, CA, which was organized last week. Getting organized is the first step towards getting benefits. Report your job on ICG600.com. Link in bio.

#UnionStrong #UnionMade #1u @iatse.bsky.social
May 19, 2025 at 10:00 PM
newsen.bsky.social
Ono's ROMVIMZA Approval Disrupts Tenosynovial Giant Cell Tumor Market Dynamics#United_States#Daiichi_Sankyo#Las_Vegas#ROMVIMZA#TGCT
Ono's ROMVIMZA Approval Disrupts Tenosynovial Giant Cell Tumor Market Dynamics
Ono Pharmaceuticals' recent FDA approval of ROMVIMZA for tenosynovial giant cell tumors introduces significant competition against Daiichi Sankyo's TURALIO.
third-news.com
March 4, 2025 at 10:52 PM
newsen.bsky.social
Ono Pharmaceuticals' ROMVIMZA Approval Disrupts TGCT Treatment Market, Challenging TURALIO#None#Tenosynovial#ROMVIMZA#TURALIO
Ono Pharmaceuticals' ROMVIMZA Approval Disrupts TGCT Treatment Market, Challenging TURALIO
Ono Pharmaceuticals secures FDA approval for ROMVIMZA, a new treatment for tenosynovial giant cell tumors, competing against Daiichi Sankyo's TURALIO.
third-news.com
March 4, 2025 at 10:42 PM
nfbot.bsky.social
[RECRUITING] Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tum
[RECRUITING] Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tum
News update via NF Bot
clinicaltrials.gov
May 28, 2026 at 1:28 AM
l2plabs.bsky.social
Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight
On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places Ono in direct competition with another Japanese pharmaceutical…
dlvr.it
March 5, 2025 at 12:13 AM
oncoassist.bsky.social
💫 #ONCOnews💫
🚨BREAKING: TURALIO® (Pexidartinib) Shows Sustained Benefit in TGCT

📊 Final long-term results from the ENLIVEN Phase 3 open-label extension show durable clinical benefit of TURALIO® in patients with TGCT

🔗 Read more: bit.ly/ONCOnews10JU-2

#OncoAlert #OncEd #ClinicalTrials #Oncology
July 10, 2025 at 1:30 PM